Write your message
Volume 3, Issue 1 (Winter 2018)                   J Obstet Gynecol Cancer Res 2018, 3(1): 19-22 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ahmadzadeh A, Shahbazian N, Arkavazi B. Examining CA 19-9 Tumor Marker in Ovarian Dermoid Cysts; A Retrospective Study. J Obstet Gynecol Cancer Res 2018; 3 (1) :19-22
URL: http://jogcr.ir/article-1-175-en.html
1- Obstetrics & Gynecology Department, Medicine Faculty, Jundishapur University of Medical Sciences, Ahvaz, Iran.
2- Obstetrics & Gynecology Department, Infertility & Perinatology Research Center, Jundishapur University of Medical Sciences, Ahvaz, Iran.
3- Student Research Committee, Jundishapur University of Medical Sciences, Ahvaz, Iran , dr.arkavazi@gmail.com
Abstract:   (3664 Views)
Aims Tumor markers are very applicable for examining differential diagnoses of adenosine masses. Increases in CA 19-9 have been reported in epithelial ovarian and endometrial tumors. Dermoid cysts are the most prevalent ovarian germ cell tumors. The aim of the present study was to examine Cancer Antigen 19-9 (CA 19-9) tumor marker in ovarian dermoid cysts.
Information and Methods This descriptive-analytic study was conducted using hospital records. By referring to archives of a Imam Khomeini Hospital, Ahwaz, Iran in 2016, the information of 73 patients with ovarian dermoid cysts were extracted that include their demographic information, cyst size, the location of involvement, the presence of symptoms of malignancy in sonography reports, and CA 19-9 serum levels prior to surgery. A pathologic report was used for the final mass diagnosis and determining the type of mass extracted from the patients’ bodies. Data were analyzed by SPSS 22 software using independent-sample t-test, chi-square test and Pearson correlation coefficient.
Findings All patients under study were diagnosed with dermoid cysts. In 9 patients (12.85%), symptoms of malignancy were reported in their sonography reports. The mean serum levels of CA 19-9 tumor marker was 46.13±11.65U/ml. There was a direct correlation between mass size and CA 19-9 serum concentrations (r=0.24). In 20% of the patients, the concentrations of CA 19-9 were normal.
Conclusion The CA 19-9 serum concentration is related to tumor size in cases of mature cystic teratoma. In most cases of unilateral mature cystic teratomas, the right ovary is mainly preferred to involve. 
Full-Text [PDF 397 kb]   (3080 Downloads)    
Systematic Review: Original Research | Subject: Obstetrics and Gynecology
Received: 2018/06/1 | Accepted: 2018/06/20 | Published: 2018/06/26

1. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: A 10-year review. Obstet Gynecol. 1989;74(6):921-6.
2. Whitecar MP, Turner S, Higby MK. Adnexal masses in pregnancy: A review of 130 cases undergoing surgical management. Am J Obstet Gynecol. 1999;181(1):19-24. [DOI:10.1016/S0002-9378(99)70429-1]
3. Bazot M, Cortez A, Sananes S, Boudghène F, Uzan S, Bigot JM. Imaging of dermoid cysts with foci of immature tissue. J Comput Assist Tomogr. 1999;23(5):703-6. [DOI:10.1097/00004728-199909000-00012] [PMID]
4. Linder D, McCaw BK, Hecht F. Parthenogenic origin of benign ovarian teratomas. N Engl J Med. 1975;292(2):63-6. [DOI:10.1056/NEJM197501092920202] [PMID]
5. Caruso PA, Marsh MR, Minkowitz S, Karten G. An intense clinicopathologic study of 305 teratomas of the ovary. Obstet Gynecol Surv. 1971;26(7):545-6. [DOI:10.1097/00006254-197107000-00026]
6. Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas: Tumor types and imaging characteristics. Radiographics. 2001;21(2):475-90. [DOI:10.1148/radiographics.21.2.g01mr09475] [PMID]
7. Fong ZV, Winter JM. Biomarkers in pancreatic cancer: Diagnostic, prognostic, and predictive. Cancer J. 2012;18(6):530-8. [DOI:10.1097/PPO.0b013e31827654ea] [PMID]
8. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31(2):164-9. [DOI:10.1016/j.ejso.2004.09.007] [PMID]
9. Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, et al. CA19-9 as the most significant prognostic indicator of etastatic colorectal cancer. Hepatogastroenterology. 2002;49(43):160-4.
10. Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Haşimi A. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer. 2006;16(1):189-93. [DOI:10.1111/j.1525-1438.2006.00284.x] [PMID]
11. Kyung MS, Choi JS, Hong SH, Kim HS. Elevated CA 19-9 levels in mature cystic teratoma of the ovary. Int J Biol Markers. 2009;24(1):52-6. https://doi.org/10.5301/JBM.2009.3363 [DOI:10.1177/172460080902400108] [PMID]
12. Var T, Tonguc EA, Ugur M, Altinbas S, Tokmak A. Tumor markers panel and tumor size of ovarian dermoid tumors in reproductive age. Bratisl Lek Listy. 2012;113(2):95-8. [DOI:10.4149/BLL_2012_022] [PMID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2024 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.